Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sérgio Chacim is active.

Publication


Featured researches published by Sérgio Chacim.


Journal of Child Neurology | 2015

Posterior Reversible Encephalopathy Syndrome in Children With Hematologic Malignancies.

Márcio Tavares; Mavilde Arantes; Sérgio Chacim; António Campos Júnior; Armando Pinto; Jose Mario Mariz; Teresa Sonin; Susana Pereira

Since its original description 2 decades ago, posterior reversible encephalopathy syndrome has been reported in children with several predisposing conditions. Epidemiologic data of posterior reversible encephalopathy syndrome in children with hematologic malignancies is still scarce. Herein, we describe the clinical and radiologic features along with the outcome and follow-up of posterior reversible encephalopathy syndrome complicating the treatment of children with hematologic malignancies. Ten patients with a median age of 6.3 years were diagnosed with posterior reversible encephalopathy syndrome. Six of them were undergoing chemotherapy and the remaining 4 were at 37, 52, 78, and 857 days after allogenic hematopoietic stem cell transplant. The median follow-up was 27.6 months. Even though follow-up imaging showed complete resolution of abnormalities in those 10 children, 2 developed secondary epilepsy. Despite accurate diagnosis of posterior reversible encephalopathy syndrome and immediate intervention, neurologic sequelae may still develop. Thus, a close follow-up should be considered in all patients.


Journal of Intensive Care Medicine | 2018

Withdrawing and Withholding Life Support in Patients With Cancer in an ICU Setting: A 5-Year Experience at a European Cancer Center.

Márcio Tavares; Inês Neves; Sérgio Chacim; Fernando Coelho; Ofélia Afonso; Anabela Martins; J. Mário Mariz; Filomena Faria

Objective: This was an observational retrospective study aimed to examine the frequency and associated factors of withdrawing or withholding life support (WWLS) in the intensive care unit (ICU) of a comprehensive cancer center. Methods: Medical records of adult patients with cancer admitted to the ICU between January 2010 and December 2014 were reviewed. Patients who died during that period were classified into 2 groups: full life support and withdrawing and withholding life support. The relative impact of demographic and clinical factors was assessed using logistic regression. Results: A total of 247 patients died in our unit (mortality rate of 16.3%). Their median age was 62 (interquartile range [IQR] 51-73) years, there were 142 (57.5%) male patients, and they had predominantly solid malignancies (62.3%). The median Simplified Acute Physiology Score II and Acute Physiology and Chronic Health Evaluation scores were 67 (IQR 54-80) and 29 (IQR 23-55), respectively. Ninety-six (38.9%) patients died after WWLS with no statistically significant differences in decisions to limit therapy during the study period. Patients with advanced age, solid malignancies, nonneutropenic, and longer duration of mechanical ventilation were more likely to die after WWLS. In multivariate analysis, presenting with neutropenia was independently associated with a lower likelihood of dying after WWLS (odds ratio: 0.34, 95% confidence interval: 0.15-0.80). Conclusion: Limitation of therapy has been a common practice in oncologic ICUs over recent years. Neutropenia is an independent predictor of limitation of therapy.


Journal of Hematology and Thromboembolic Diseases | 2015

Treatment Outcomes of Patients with Primary Mediastinal Diffuse Large B-CellLymphoma: A Single-Center Experience

Márcio Tavares; Ana Margarida Simas; Carla Castro; Ana Espirito Santo; Nelson Domingues; Isabel Oliveira; Ângelo Martins; Ilidia Moreira; Luisa Viterbo; Ângelo Oliveira; Rui Henrique; Sérgio Chacim; Jose Mario Mariz

Background: Primary mediastinal B-cell lymphoma (PMBCL) is a distinct clinicopathologic entity from diffuse large B-cell lymphoma. The optimal first-line therapy for PMBCL is subject of ongoing debate with no accepted standard of care. Patients and Methods: We searched retrospectively for adult patients with newly diagnosed PMBCL treated at our department between 2002 and 2014. Clinical, management and follow-up data were collected. Staging and response assessment of patients included PET and/or CT scan. Results: Twenty-nine patients with PMBCL (17 female and 12 male) were included. The median age at diagnosis was 36 years (18-79 years). Eighteen (62.1%) and 20 (69%) patients had limited-stage and bulky disease, respectively. All patients were treated with rituximab-based combination chemotherapy; 21 patients underwent consolidation radiotherapy. Seven patients (24.1%) were transplanted (six in first remission and the remaining in second remission). At the end of frontline therapy, 28 patients had responded (27 complete response and 1 partial response) and one patient showed progressive disease. Febrile neutropenia was the most frequent acute adverse event and three patients developed late toxicity. The median follow-up was 51,5 months. The 5-year overall progression-free survival was 83.8%. Four patients died, half of which died within the first year after diagnosis. Conclusion: Our study shows favorable prognosis of patients with PMBCL treated with rituximab-based chemotherapy and consolidation radiotherapy or autologous stem-cell transplant. While consolidation therapy continues to be commonly used, its role has become increasingly controversial.


Case reports in hematology | 2014

Secondary hemophagocytic syndrome: the importance of clinical suspicion.

Cristina Oliveira; Sérgio Chacim; Isabel Ferreira; Nelson Domingues; Jose Mario Mariz

Hemophagocytic syndrome is a rare and potentially fatal disorder characterized by pathological immune activation associated with a primary familial disorder, genetic mutations, or occurring as a sporadic condition. The latter can be secondary to infections, malignancies, or autoimmune diseases. Clinically, patients present signs of severe inflammation, with unremitting fever, cytopenias, spleen enlargement, phagocytosis of bone marrow elements, hypertriglyceridemia, and hypofibrinogenemia. Increased suspicion is determinant to timely initiate treatment in an attempt to alter the natural history. The authors present three clinical cases of this syndrome, with a brief review of the diagnostic criteria and treatment.


Supportive Care in Cancer | 2014

Mucositis care in acute leukemia and non-Hodgkin lymphoma patients undergoing high-dose chemotherapy

Jose Martinez; Dulcineia Pereira; Sérgio Chacim; Edgar Mesquita; Inês Sousa; Ângelo Martins; Teresa Azevedo; Jose Mario Mariz


Oncology Letters | 2016

Effect of therapy-related acute myeloid leukemia on the outcome of patients with acute myeloid leukemia

Ana Espirito Santo; Sérgio Chacim; Isabel Ferreira; Luís Leite; Claudia Moreira; Dulcineia Pereira; Margarida Dantas Dantas Brito; M. U. C. Nunes; Nelson Domingues; Isabel Oliveira; Ilidia Moreira; Angelo Martins; Luisa Viterbo; Jose Mario Mariz; Rui Medeiros


Clinical Lymphoma, Myeloma & Leukemia | 2014

What Determines Therapeutic Choices for Elderly Patients With DLBCL? Clinical Findings of a Multicenter Study in Portugal

Rute Alvarez; Susana Esteves; Sérgio Chacim; José Pedro Carda; Alexandra Mota; Manuel Guerreiro; Inês Barbosa; Filipa Moita; Adriana Teixeira; Jorge Coutinho; Fernando Príncipe; Jose Mario Mariz; Maria Gomes da Silva


Blood | 2012

Prognostic Impact of High Hematogones in Acute Myeloid Leukemia

Dulcineia Pereira; Sérgio Chacim; Edgar Mesquita; Ana Espirito-Santo; Ilidia Moreira; Nelson Domingues; Isabel Oliveira; Luisa Viterbo; M. G. Marques; Carlos Palmeira; Maria Emília Sousa; Inês Godinho; Ana Marta Pires; Nuno Cerveira; Susana Bizarro; Manuel R. Teixeira; Ângelo Martins; Gabriela Martins; Jose Mario Mariz


Journal of Cancer Therapy | 2018

Fever and Infection Prevalence in Hematology-Oncology Hospitalized Patients: A Single-Center Retrospective Study

Inês Almeida Costa; Sérgio Chacim; Jose Mario Mariz


Molecular and Clinical Oncology | 2017

Southwestern Oncology Group pretreatment risk criteria as predictive or prognostic factors in acute myeloid leukemia

Ana Espirito Santo; Sérgio Chacim; Isabel Ferreira; Luís Leite; Claudia Moreira; Dulcineia Pereira; Margarida Dantas; M. U. C. Nunes; Luisa Viterbo; Ilidia Moreira; Angelo Martins; Isabel Oliveira; Nelson Domingues; Jose Mario Mariz; Rui Medeiros

Collaboration


Dive into the Sérgio Chacim's collaboration.

Top Co-Authors

Avatar

Jose Mario Mariz

Instituto Português de Oncologia Francisco Gentil

View shared research outputs
Top Co-Authors

Avatar

Nelson Domingues

Instituto Português de Oncologia Francisco Gentil

View shared research outputs
Top Co-Authors

Avatar

Dulcineia Pereira

Instituto Português de Oncologia Francisco Gentil

View shared research outputs
Top Co-Authors

Avatar

Ilidia Moreira

Instituto Português de Oncologia Francisco Gentil

View shared research outputs
Top Co-Authors

Avatar

Isabel Oliveira

Instituto Português de Oncologia Francisco Gentil

View shared research outputs
Top Co-Authors

Avatar

Luisa Viterbo

Instituto Português de Oncologia Francisco Gentil

View shared research outputs
Top Co-Authors

Avatar

Angelo Martins

Instituto Português de Oncologia Francisco Gentil

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ana Espirito-Santo

Instituto Português de Oncologia Francisco Gentil

View shared research outputs
Top Co-Authors

Avatar

Claudia Moreira

Instituto Português de Oncologia Francisco Gentil

View shared research outputs
Researchain Logo
Decentralizing Knowledge